Sensorion Will Present Two Posters At The American Society Of Cell And Gene Therapy (ASGCT) 26th Annual Meeting
11 May 2023 - 3:30PM
Business Wire
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering
clinical-stage biotechnology company which specializes in gene
therapies in the ear, is pleased to announce its participation in
the ASGCT Annual Meeting taking place on May 16-20, 2023, in Los
Angeles, USA. Géraldine Honnet, M.D., Chief Medical Officer and
Laurent Désiré, Ph.D., Head of Preclinical Development will
participate in-person.
Sensorion will present the two following posters at the
ASGCT 26th Annual Meeting:
- “An Integrated Adeno-Associated Vector Development Platform
for Inner Ear Disorders” (poster board number: 459), the poster
session will take place on Wednesday May 17, 2023, from 12.00pm to
2.00pm PDT. An abstract of the poster can be found here.
- “Preclinical Development of an Adeno Associated Vector-Based
Gene Therapy (SENS-501) for the Autosomal Recessive Non-Syndromic
Deafness 9 (DFNB9)” (poster board number: 946), the poster
session will take place on Thursday May 18, 2023, from 12.00pm to
2.00pm PDT. An abstract of the poster can be found here.
About Sensorion Sensorion is a pioneering clinical-stage
biotech company, which specializes in the development of gene
therapies to restore hearing loss disorders, a significant global
unmet medical need.
Sensorion has built a unique R&D technology platform to
expand its understanding of the pathophysiology and etiology of
inner ear related diseases, enabling it to select the best targets
and mechanisms of action for drug candidates.
It has two gene therapy programs aimed at correcting hereditary
monogenic forms of deafness, developed in the framework of its
broad strategic collaboration focused on the genetics of hearing
with the Institut Pasteur. OTOF-GT targets deafness caused by
mutations of the gene encoding for otoferlin and GJB2-GT targets
hearing loss related to mutations in GJB2 gene to potentially
address important hearing loss segments in adults and children. The
Company is also working on the identification of biomarkers to
improve diagnosis of these underserved illnesses.
Sensorion’s portfolio also comprises clinical-stage small
molecule programs for the treatment and prevention of hearing loss
disorders.
Sensorion’s clinical-stage portfolio includes one Phase 2
product: SENS-401 (Arazasetron) progressing in a planned Phase 2
proof of concept clinical study of SENS-401 in Cisplatin-Induced
Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of
SENS-401 in patients scheduled for cochlear implantation. A Phase 2
study of SENS-401 was also completed in Sudden Sensorineural
Hearing Loss (SSNHL) in January 2022.
www.sensorion.com
Label: SENSORION ISIN: FR0012596468 Mnemonic:
ALSEN
Disclaimer This press release contains certain
forward-looking statements concerning Sensorion and its business.
Such forward looking statements are based on assumptions that
Sensorion considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the 2022 full year financial report published on March
30, 2023, and available on our website and to the development of
economic conditions, financial markets and the markets in which
Sensorion operates. The forward-looking statements contained in
this press release are also subject to risks not yet known to
Sensorion or not currently considered material by Sensorion. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Sensorion to
be materially different from such forward-looking statements. This
press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Sensorion shares in any
country. The communication of this press release in certain
countries may constitute a violation of local laws and regulations.
Any recipient of this press release must inform oneself of any such
local restrictions and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230510005654/en/
Investor Relations David Lawrence, Chief Financial
Officer (US/UK) Noémie Djokovic, Investor Relations and
Communications (Europe/France) ir.contact@sensorion-pharma.com
International Media Relations Consilium1Strategic
Communications Matthew Cole/Jessica Hodgson/Sue Stuart +44 7593
572720 +44 7561 424788 Sensorion@consilium-comms.com
Sensorion (EU:ALSEN)
Historical Stock Chart
From Apr 2024 to May 2024
Sensorion (EU:ALSEN)
Historical Stock Chart
From May 2023 to May 2024